Substituted heterocyclic compounds with CXCR3 antagonist activity
View Patent ↗The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: or a pharmaceutically acceptable salt, solvate or ester thereof, wherein the various moieties are defined herein. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, type I diabetes, viral meningitis and tumors using a compound of Formula 1.
1. A compound having the structure shown in Formula 1:
or a pharmaceutically acceptable salt thereof, wherein:
G is selected from the group consisting of H 2 N(C═O)—and a 5-membered heteroaryl or heterocyclenyl ring, said 5-membered heteroaryl or heterocyclenyl ring is selected from the group consisiting of dihydroimidazole, imidazole, dihydrooxazole, oxazole, dihydrooxadiazole, oxadiazole, triazole, and tetrazole, and wherein said heteroaryl or heterocyclenyl ring can be either (i) unsubstituted, or (ii) optionally independently substituted on one or more ring carbon atoms with one or more R 9 substituents,
L is O;
Z is N;
R 3 is H, alkyl, —CN, haloalkyl or halogen;
R 6 is selected from the group consisting of H, alkyl, arylalkyl, and alkylaryl;
the R 9 moieties can be the same or different, each being independently selected from the group consisting of H, —CF 3 , —CH 2 CH 2 OH, —CH 2 CH 2 NH 2 , —NH 2 , —NHCH 3 , —N(H)CH 2 CH 3 , —N(H)CH(CH 3 ) 2 , —N(H)CH 2 CH 2 CH 3 , —N(H)CH 2 C(═O)OCH 3 , and —N(H)CH 2 CH 2 OH;
the R 10 moieties can be the same or different, each being independently selected from the group consisting of H and alkyl;
the R 11 moieties can be the same or different, each being independently selected from the group consisting of H and alkyl;
R 12 is H or alkyl;
ring D is a six membered aryl or heteroaryl ring having 0-4 N heteroatoms, wherein ring D is unsubstituted or optionally substituted with 1-5 independently selected R 20 moieties;
the R 20 moieties can be the same or different, each being independently selected from the group consisting of H, alkyl, halogen, and amino,
Y is selected from the group consisting of —CH 2 —and —C(═O)—;
m is 0 to 2;
n is 0 to 2.
2. The compound according to claim 1 , wherein G is
3. The compound according to claim 1 , wherein R 3 is selected from the group consisting of H, —Cl and —CH 3 .
4. The compound according to claim 1 , wherein the R 9 moiety is selected from the group consisting of —NH 2 and —N(H)CH 2 CH 3 .
5. The compound according to claim 1 , wherein R 10 is alkyl.
6. The compound according to claim 5 , wherein said alkyl is selected from the group consisting of —CH 3 , —CH 2 CH 3 and —CH 2 CH 2 CH 3 .
7. The compound according to claim 6 , wherein R 10 is —CH 2 CH 3 and m is 1.
8. The compound according to claim 1 , wherein ring D is substituted by 1-4 R 20 moieties.
9. The compound according to claim 1 , wherein said aryl ring of D is phenyl and said heteroaryl ring of D is pyridyl.
10. The compound according to claim 1 , wherein m is 1.
11. The compound according to claim 1 , wherein G is selected independently from the group consisting of H 2 N(C═O)—and
R 3 is selected from the group consisting of H, —Cl and —CH 3 ;
R 9 is selected from the group consisting of H, —Cl and —CH 3 ;
R 10 is —CH 2 CH 3 ;
R 11 is H;
R 12 is H;
ring D is a 6 membered aryl, or heteroaryl ring and substituted by 1-4 R 20 moieties;
R 20 moieties can be the same or different, each being independently selected from the group consisting of H, halogen, and amino;
Y is selected from the group consisting of: —CH 2 —, and —C(═O)—;
m is 1; and
n is 0.
12. A compound selected from the group consisting of the following:
or a pharmaceutically acceptable salt thereof.
13. A compound according to claim 12 , wherein the compound is selected from the group consisting of
or a pharmaceutically acceptable salt thereof.
14. A compound according to claim 1 in purified form.
15. A pharmaceutical composition comprising at least one compound of claim 1 , or a pharmaceutically acceptable salt thereof, in combination with at least one pharmaceutically acceptable carrier.